110 related articles for article (PubMed ID: 29889136)
21. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
23. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
25. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
27. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
28. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
29. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
31.
Vallius T; Hynninen J; Kemppainen J; Alves V; Auranen K; Matomäki J; Oksa S; Virtanen J; Grénman S; Auranen A; Seppänen M
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1224-1232. PubMed ID: 29476227
[TBL] [Abstract][Full Text] [Related]
32. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
33. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
[TBL] [Abstract][Full Text] [Related]
34. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
Horner W; Peng K; Pleasant V; Brackmann M; Ebott J; Gutfreund R; McLean K; Reynolds RK; Uppal S
Gynecol Oncol; 2019 Aug; 154(2):283-289. PubMed ID: 31196575
[TBL] [Abstract][Full Text] [Related]
35. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.
Dewdney SB; Rimel BJ; Reinhart AJ; Kizer NT; Brooks RA; Massad LS; Zighelboim I
Gynecol Oncol; 2010 Oct; 119(1):18-21. PubMed ID: 20673970
[TBL] [Abstract][Full Text] [Related]
36. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
37. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
38. Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor.
Lu Y; Yang J; Cao D; Huang H; Wu M; You Y; Chen J; Lang J; Shen K
Gynecol Oncol; 2014 Jul; 134(1):78-83. PubMed ID: 24582864
[TBL] [Abstract][Full Text] [Related]
39. A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
Eoh KJ; Yoon JW; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
BMC Cancer; 2017 Jul; 17(1):481. PubMed ID: 28701190
[TBL] [Abstract][Full Text] [Related]
40. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
